{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:22Z","timestamp":1792460122439,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12253-019-00666-5","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T19:20:11Z","timestamp":1557516011000},"page":"1105-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy"],"prefix":"10.1007","volume":"26","author":[{"given":"Yung-Sung","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Lin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yii","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000345742","volume":"58","author":"YS Yeh","year":"2015","unstructured":"Yeh YS, Tsai HL, Ma CJ, Wu DC, Lu CY, Wu IC, Hou MF, Wang JY (2015) A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Chemotherapy 58:411\u2013418","journal-title":"Chemotherapy"},{"key":"666_CR2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, J\u00e4ger E, Arbeitsgemeinschaft Internistische Onkologie (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435\u20131342","journal-title":"J Clin Oncol"},{"key":"666_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Trial Participants MAGIC (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11\u201320","journal-title":"N Engl J Med"},{"key":"666_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-013-2073-5","volume":"71","author":"M Hirakawa","year":"2013","unstructured":"Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J (2013) A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 71:789\u2013797","journal-title":"Cancer Chemother Pharmacol"},{"key":"666_CR5","volume":"8","author":"B Colton","year":"2016","unstructured":"Colton B, Hartley M, Manning MA, Carroll JE, Xiu J, Smaglo BG, Mikhail S, Salem ME (2016) Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. Cureus 8:e457","journal-title":"Cureus"},{"key":"666_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.23422","volume":"108","author":"MY Huang","year":"2013","unstructured":"Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, Chai CY, Wang JY (2013) Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol 108:457\u2013464","journal-title":"J Surg Oncol"},{"key":"666_CR7","first-page":"227","volume":"1","author":"E Raymond","year":"2002","unstructured":"Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227\u2013235","journal-title":"Mol Cancer Ther"},{"key":"666_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/FPC.0b013e3283415124","volume":"21","author":"MY Huang","year":"2011","unstructured":"Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY (2011) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21:18\u201325","journal-title":"Pharmacogenet Genomics"},{"key":"666_CR9","first-page":"gmr.15027384","volume":"15","author":"DL Zheng","year":"2016","unstructured":"Zheng DL, Tang GD, Chen YN, Zhang T, Qin MB (2016) Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. Genet Mol Res 15:gmr.15027384","journal-title":"Genet Mol Res"},{"key":"666_CR10","doi-asserted-by":"crossref","unstructured":"Edge SB Compton (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. CC. Ann Surg Oncol 17:1471\u20131474","DOI":"10.1245\/s10434-010-0985-4"},{"key":"666_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.pas.0000146009.85309.3b","volume":"29","author":"J Shia","year":"2005","unstructured":"Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, Gerald WL, Ellis NA (2005) Value of Immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 29:96\u2013104","journal-title":"Am J Surg Pathol"},{"key":"666_CR12","doi-asserted-by":"publisher","first-page":"15921","DOI":"10.4238\/2015.December.7.3","volume":"14","author":"YY Zhang","year":"2015","unstructured":"Zhang YY, Gu KS, Wu HY, Yang F, Bu LJ, Zhao CC, Zhang YR (2015) Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Genet Mol Res 14:15921\u201315929","journal-title":"Genet Mol Res"},{"key":"666_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney S, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053\u20131071","journal-title":"Ann Oncol"},{"key":"666_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/JTO.0b013e31815ba2a1","volume":"2","author":"R Rosell","year":"2007","unstructured":"Rosell R, Mendez P, Isla D, Taron M (2007) Platinum resistance related to a functional NER pathway. J Thorac Oncol 2:1063\u20131066","journal-title":"J Thorac Oncol"},{"key":"666_CR15","first-page":"13367","volume":"8","author":"Y Bai","year":"2015","unstructured":"Bai Y, Wang L, Li G, Fang X, Li Y, Yang S (2015) Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer. Int J Clin Exp Pathol 8:13367\u201313373","journal-title":"Int J Clin Exp Pathol"},{"key":"666_CR16","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/carcin\/bgh264","volume":"25","author":"O Popanda","year":"2004","unstructured":"Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L, Kayser K, Dienemann H, Schulz V, Drings P, Bartsch H, Schmezer P (2004) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 25:2433\u20132441","journal-title":"Carcinogenesis"},{"key":"666_CR17","first-page":"5563","volume":"8","author":"MH Xue","year":"2015","unstructured":"Xue MH, Li GY, Wu XJ, Zhang CX, Zhang CF, Zhu KX (2015) Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Int J Clin Exp Pathol 8:5563\u20135569","journal-title":"Int J Clin Exp Pathol"},{"key":"666_CR18","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-04-1387","volume":"11","author":"MB Joshi","year":"2005","unstructured":"Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr (2005) High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11:2215\u20132221","journal-title":"Clin Cancer Res"},{"key":"666_CR19","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298\u20134304","journal-title":"J Clin Oncol"},{"key":"666_CR20","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1007\/s00268-017-4070-z","volume":"41","author":"MY Huang","year":"2017","unstructured":"Huang MY, Huang JJ, Huang CM, Lin CH, Tsai HL, Huang CW, Chai CY, Lin CY, Wang JY (2017) Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. World J Surg 41:2884\u20132897","journal-title":"World J Surg"},{"key":"666_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1378\/chest.127.3.978","volume":"127","author":"G Simon","year":"2005","unstructured":"Simon G, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978\u2013983","journal-title":"Chest"},{"key":"666_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1172\/JCI117388","volume":"94","author":"M Dabholkar","year":"1994","unstructured":"Dabholkar M, Vionnet J, Bostick-Bruton FYJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703\u2013708","journal-title":"J Clin Invest"},{"key":"666_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/annonc\/mdl435","volume":"18","author":"J Bellmunt","year":"2007","unstructured":"Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J, Spanish Oncology Genitourinary Group (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18:522\u2013528","journal-title":"Ann Oncol"},{"key":"666_CR24","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/sj.bjc.6605686","volume":"102","author":"KR Fareed","year":"2010","unstructured":"Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S (2010) Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102:1600\u20131607","journal-title":"Br J Cancer"},{"key":"666_CR25","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.3748\/wjg.v16.i44.5621","volume":"16","author":"W Li","year":"2010","unstructured":"Li W, Qin J, Sun YH, Liu TS (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 16:5621\u20135628","journal-title":"World J Gastroenterol"},{"key":"666_CR26","doi-asserted-by":"publisher","first-page":"vi120","DOI":"10.1093\/annonc\/mdm239","volume":"18","author":"F De Vita","year":"2007","unstructured":"De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M (2007) Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 18:vi120\u2013vi123","journal-title":"Ann Oncol"},{"key":"666_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jso.21483","volume":"101","author":"JJ Mezhir","year":"2010","unstructured":"Mezhir JJ, Tang LH, Coit DG (2010) Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 101:305\u2013314","journal-title":"J Surg Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-019-00666-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T13:23:13Z","timestamp":1590067393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-019-00666-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s12253-019-00666-5","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"13 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}